Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.73 |
| ▸ | CA1 | P00915 | 7/20 | 0.73 |
| ▸ | CA2 | P00918 | 7/20 | 0.73 |
| ▸ | CA9 | Q16790 | 7/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | SUCNR1 | Q9BXA5 | 7/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2229323 | 0.96 | CA1 (0.72) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL5420417 | 0.92 | CA12 (0.71) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL23817033 | 0.88 | CA12 (0.67) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL30440313 | 0.87 | CA12 (0.70) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL14313674 | 0.87 | CA12 (0.70) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL17162044 | 0.86 | CA12 (0.62) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL10253852 | 0.86 | CA12 (0.66) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL2228195 | 0.86 | CA12 (0.62) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL2147505 | 0.86 | CA12 (0.69) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL12709532 | 0.85 | CA1 (0.70) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-03-06 | — | — | US | disclosed |
| CN-117838875-B | Drug delivery system for local delivery of therapeutic agents and uses thereof | 上海椿安生物医药科技有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-117838875-A | Drug delivery system for local delivery of therapeutic agents and uses thereof | 上海椿安生物医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-115867319-B | Drug delivery system for local delivery of therapeutic agents and uses thereof | 上海椿安生物医药科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230256106-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230256106-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230256106-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| WO-2023091565-A1 | NSD2-TARGETED CHEMICAL DEGRADERS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023091565-A1 | NSD2-TARGETED CHEMICAL DEGRADERS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2022012492-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2022-01-20 | — | — | WO | disclosed |
| US-9861635-B2 | Macrocycles as kinase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-9861635-B2 | Macrocycles as kinase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| EP-2994471-B1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2017-05-17 | — | — | EP | disclosed |
| EP-2994471-B1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2017-05-17 | — | — | EP | disclosed |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| EP-2994471-A1 | MACROCYCLES AS KINASE INHIBITORS | Merck Patent GmbH (DE) | 2016-03-16 | — | — | EP | disclosed |
| WO-2014180524-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256106-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | TIE1, TEK, KDR | CA12 571/4885CA1 2306/4885CA2 1171/4885 |
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | NCOR2, NSD2, NCOR1 | CA12 4129/4885CA1 4590/4885CA2 4561/4885 |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | EIF2AK4, CDK2, CDK1 | CA12 4590/4885CA1 4552/4885CA2 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.